1. Profusa's Lumee technology accepted for presentation at Leipzig Interventional Course 2026. 2. New insights on tissue oxygen monitoring for PAD patients will be discussed. 3. Positive feedback received from U.S. pilot clinical study on Lumee technology. 4. Profusa focuses on continuous monitoring of biochemical data for medical use. 5. The acceptance signifies potential investor interest and market validation for PFSA.
FAQ
Why Bullish?
The acceptance of Profusa's work at a prestigious conference may enhance credibility and visibility. Previous instances where companies presented at major events often saw subsequent stock price increases as investor interest grew.
How important is it?
The article underscores a pivotal moment in Profusa's advancement and public perception. The presentation could attract new investment and partners, which is critical for growth and profitability.
Why Short Term?
The immediate upcoming presentation creates short-term interest and possible stock movement. Typically, news around significant events can propagate enthusiasm and speculative buying prior to and following the event.
Profusa to Present Clinical Data on Lumee Technology at LINC 2026
BERKELEY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a cutting-edge digital health company focused on continuous biochemical monitoring, has announced the acceptance of its abstract for presentation at the Leipzig Interventional Course (LINC) 2026. This prestigious event is scheduled to take place from January 27 to 30, 2026, in Leipzig, Germany.
Key Insights on Peripheral Artery Disease Monitoring
During the conference, Profusa will delve into findings from its U.S. pilot clinical study, which evaluates the effectiveness of its Lumee™ oxygen monitoring technology in patients with peripheral artery disease (PAD). The presentation is set for January 28, 2026, at 9:45 AM CET in Hall 2 of the Trade Fair Leipzig.
Ben Hwang, Ph.D., Chairman and CEO of Profusa, commented, “Our proprietary Lumee oxygen tissue monitoring technology enables continuous, real-time measurement of tissue oxygen directly within the body, intended for use both in the clinic and at home.” He added that feedback from the study has been positive, and the upcoming conference will provide an excellent platform for sharing more clinical results with healthcare providers and researchers.
About Profusa and Its Innovations
Profusa stands at the forefront of digital health innovation, located in Berkeley, California. The company is dedicated to the development of advanced tissue-integrated sensors that provide actionable, medical-grade data. Profusa’s biosensors are designed to be long-lasting, cost-effective, and injectable, enabling continuous monitoring of vital biochemical data.
- Company Name: Profusa, Inc.
- Stock Symbol: PFSA
- Product: Lumee™ oxygen monitoring technology
- Focus Area: Peripheral artery disease (PAD)
Forward-Looking Statements Disclaimer
Investors are advised that certain statements made in this press release may be construed as forward-looking statements, as defined by the U.S. Private Securities Litigation Reform Act of 1995. These statements, which may concern future events or the operational performance of Profusa, are subject to risks and uncertainties that could result in actual outcomes differing significantly from those projected.
The company encourages potential investors to review documents filed with the SEC that detail further risks associated with their operations and forward-looking projections.